Abstract
Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively. BEAM, Z-BEAM and R-BEAM groups were well balanced for age, time from diagnosis to ASCT and disease status at ASCT. The cumulative incidences of relapse (IR) at 2 years were 34, 34 and 32% for Z-BEAM, R-BEAM and BEAM, respectively. By multivariate analysis, there were no significant differences with Z-BEAM or R-BEAM compared with BEAM for IR, non-relapse mortality, event-free survival or overall survival. With the caveat that the limitations of registry analyses have to be taken into account, this study does not support adding radioimmunotherapy or R to BEAM in ASCT for relapsed FL. However, we cannot rule out ...Continue Reading
References
May 17, 2003·Blood·Ajay K GopalOliver W Press
Feb 26, 2005·Blood·John M BennettRobert L Capizzi
Jul 9, 2005·Blood·Auayporn NademaneeAndrew Raubitschek
Oct 28, 2006·Annals of Hematology·M DreylingM Freund
Mar 24, 2007·Experimental Hematology·Avichai ShimoniArnon Nagler
May 23, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ama Z S RohatinerArnold S Freedman
Jul 20, 2007·Leukemia·S MontotoUNKNOWN EBMT Lymphoma Working Party
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanArturo Molina
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amrita KrishnanStephen J Forman
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Liliana DevizziAlessandro M Gianni
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jane N WinterLeo I Gordon
Oct 21, 2009·The Oncologist·Christian GisselbrechtArnon Nagler
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserDavid M Goldenberg
Dec 24, 2010·Lancet·Gilles SallesHervé Tilly
May 18, 2011·Clinical Lymphoma, Myeloma & Leukemia·Didier DecaudinChristian Gisselbrecht
May 24, 2011·Leukemia & Lymphoma·Thomas E WitzigAndrew D Zelenetz
Jan 19, 2012·Cancer·Avichai ShimoniArnon Nagler
Nov 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M GhielminiUNKNOWN Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma
Mar 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie M VoseMarcie Tomblyn
Apr 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruth PettengellAnthony H Goldstone
Jul 3, 2013·Haematologica·Silvia MontotoPeter Dreger
Sep 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I El-NajjarUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DreylingUNKNOWN ESMO Guidelines Committee
Citations
Nov 6, 2018·Bone Marrow Transplantation·Parastoo B DahiSergio A Giralt
Nov 6, 2018·Bone Marrow Transplantation·Jane E NormanStephen P Robinson
Apr 11, 2020·Cancer Biotherapy & Radiopharmaceuticals·Kevin C ConlonThomas A Waldmann
Dec 7, 2019·Hematology·Victor A Chow, Ajay K Gopal
Oct 13, 2021·Blood Advances·Alex F HerreraEileen Smith